XML 60 R15.htm IDEA: XBRL DOCUMENT v3.19.3
Segment Information
 9 Months Ended
Sep. 30, 2019
Segment Information [Abstract]  
Segment Information
8.  Segment Information


We have two reportable segments, Ionis Core and Akcea Therapeutics. At September 30, 2019 we owned approximately 75 percent of Akcea. Segment income (loss) from operations includes revenue less operating expenses attributable to each segment.



In our Ionis Core segment we are exploiting our antisense technology to generate a broad pipeline of first-in-class and/or best-in-class medicines for us and our partners. Our Ionis Core segment generates revenue from a multifaceted partnering strategy.


Akcea is a biopharmaceutical company focused on developing and commercializing medicines to treat patients with rare and serious diseases. Akcea generates revenue from TEGSEDI and WAYLIVRA product sales and from its collaborations.


The following tables show our segment revenue and income (loss) from operations for the three and nine months ended September 30, 2019 and 2018 (in thousands), respectively.


Three Months Ended September 30, 2019
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
81,672
    
$
—
    
$
—
    
$
81,672
  
Product sales, net
    
—
      
11,945
      
—
      
11,945
  
Licensing and other royalty revenue
    
1,946
      
136
      
—
      
2,082
  
Total commercial revenue
    
83,618
      
12,081
      
—
      
95,699
  
R&D revenue under collaborative agreements
    
69,165
      
8,543
      
(5,515
)
    
72,193
  
Total segment revenue
  
$
152,783
    
$
20,624
    
$
(5,515
)
  
$
167,892
  
Total operating expenses
  
$
119,147
    
$
53,215
    
$
(6,993
)
  
$
165,369
  
Income (loss) from operations
  
$
33,636
    
$
(32,591
)
  
$
1,478
    
$
2,523
  

Three Months Ended September 30, 2018
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
70,010
    
$
—
    
$
—
    
$
70,010
  
Licensing and other royalty revenue
    
7,946
      
12,000
      
(7,200
)
    
12,746
  
Total commercial revenue
    
77,956
      
12,000
      
(7,200
)
    
82,756
  
R&D revenue under collaborative agreements
    
100,105
      
7,241
      
(44,707
)
    
62,639
  
Total segment revenue
  
$
178,061
    
$
19,241
    
$
(51,907
)
  
$
145,395
  
Total operating expenses
  
$
87,664
    
$
84,249
    
$
(7,946
)
  
$
163,967
  
Income (loss) from operations
  
$
90,397
    
$
(65,008
)
  
$
(43,961
)
  
$
(18,572
)

Nine Months Ended September 30, 2019
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
211,884
    
$
—
    
$
—
    
$
211,884
  
Product sales, net
    
—
      
28,563
      
—
      
28,563
  
Licensing and other royalty revenue
    
8,466
      
6,172
      
(3,000
)
    
11,638
  
Total commercial revenue
    
220,350
      
34,735
      
(3,000
)
    
252,085
  
R&D revenue under collaborative agreements
    
294,512
      
176,328
      
(94,007
)
    
376,833
  
Total segment revenue
  
$
514,862
    
$
211,063
    
$
(97,007
)
  
$
628,918
  
Total operating expenses
  
$
355,437
    
$
256,152
    
$
(87,900
)
  
$
523,689
  
Income (loss) from operations
  
$
159,425
    
$
(45,089
)
  
$
(9,107
)
  
$
105,229
  

Nine Months Ended September 30, 2018
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
167,743
    
$
—
    
$
—
    
$
167,743
  
Licensing and other royalty revenue
    
9,432
      
12,000
      
(7,200
)
    
14,232
  
Total commercial revenue
    
177,175
      
12,000
      
(7,200
)
    
181,975
  
R&D revenue under collaborative agreements
    
232,850
      
42,670
      
(49,936
)
    
225,584
  
Total segment revenue
  
$
410,025
    
$
54,670
    
$
(57,136
)
  
$
407,559
  
Total operating expenses
  
$
279,084
    
$
213,428
    
$
(12,796
)
  
$
479,716
  
Income (loss) from operations
  
$
130,941
    
$
(158,758
)
  
$
(44,340
)
  
$
(72,157
)


The following table shows our total assets by segment at September 30, 2019 and December 31, 2018 (in thousands), respectively.


Total Assets
  
Ionis Core
    
Akcea Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
September 30, 2019
  
$
3,233,175
    
$
383,167
    
$
(721,353
)
  
$
2,894,989
  
December 31, 2018
  
$
2,975,491
    
$
365,261
    
$
(672,968
)
  
$
2,667,784